Less Ads, More Data, More Tools Register for FREE

hVIVO Half-Year Loss Widens, Hit By Ebola Outbreak, Slow Flu Uptake

Thu, 24th Sep 2015 07:57

LONDON (Alliance News) - hVIVO PLC on Thursday reported widened pretax loss for the first half of 2015, hit by pharmaceutical companies continuing to divert resources to tackle the Ebola outbreak, and lower-than-expected demand for human challenge clinical trials in influenza.

hVIVO is a life sciences company focused on human challenge models for pharmaceutical and biotechnology companies, which involves inducing infections in healthy volunteers to test the efficacy of vaccines or study the progression of the disease.

For the half year to end-June, the company reported a pretax loss of GBP12.0 million, widened from a pretax loss of GBP5.4 million a year before, as a drop in revenue to GBP2.9 million from GBP15.0 million. Cost of sales also fell, but this was more than offset by higher research and development expenses.

The company attributed the fall in revenue to clients funnelling resources into tackling Ebola, and reduced demand for early phase human challenge studies in influenza. hVIVO said that in response to the changing market conditions it took actions to priorities its spend in research and development.

"I am heartened by how quickly the Ebola outbreak was contained due to the extraordinary response across the scientific and pharmaceutical communities, and I look forward to leveraging our newly acquired insight into flu as influenza clinical trial programmes regain their momentum within global pharmaceutical and biotech companies," said Chief Executive Officer Kym Denny in a statement.

Shares in hVIVO were down 5.4% at 290.00 pence Thursday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

Related Shares

More News
3 Jun 2024 12:20

hVIVO says Omicron contract validates move to Canary Wharf facility

(Alliance News) - hVIVO PLC on Monday welcomed a GBP2.5 million contract to start an Omicron characterisation study at its new facility at Canary Whar...

3 Jun 2024 10:35

Hvivo scores £2.5m contract for Omicron characterisation study

(Sharecast News) - Contract research organisation Hvivo has secured a £2.5m contract with a mid-sized pharmaceutical company to initiate an Omicr...

13 May 2024 16:16

UK dividends calendar - next 7 days

11 Apr 2024 15:09

UK dividends calendar - next 7 days

9 Apr 2024 12:03

hVIVO swings to profit and commences annual dividends as outlook rosy

(Alliance News) - hVIVO PLC on Tuesday launched an annual dividend policy, as it swung to profit on the back of higher revenue and a tax credit.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.